BWXT Medical and Canada's particle accelerator center TRIUMF have executed a licensing and services agreement that will expand their existing medical isotope production partnership.
The agreement will enable BWXT Medical to manufacture actinium-225 (Ac-225)-based products for pharmaceutical companies developing targeted alpha therapeutics. After TRIUMF irradiates thorium-232 targets, BWXT will then process and produce high-purity Ac-225 for commercial sale, according to the vendor
